Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Their Cardiovascular Benefits-The Role of the GLP-1 Receptor

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2021 Mar 25

PMID 33764504

Citations 20

Authors

Johanna Helmstadter

Karin Keppeler

Leonie Kuster

Thomas Munzel

Andreas Daiber

Sebastian Steven

Affiliations

Soon will be listed here.

Abstract

Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus patients when treated with long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. In the last decade, major advances were made characterising the physiological effects of GLP-1 and its action on numerous targets including brain, liver, kidney, heart and blood vessels. However, the effects of GLP-1 and receptor agonists, and the GLP-1 receptor on the cardiovascular system have not been fully elucidated. We compare results from cardiovascular outcome trials of GLP-1 receptor agonists and review pleiotropic clinical and preclinical data concerning cardiovascular protection beyond glycaemic control. We address current knowledge on GLP-1 and receptor agonist actions on the heart, vasculature, inflammatory cells and platelets, and discuss evidence for GLP-1 receptor-dependent versus independent effects secondary of GLP-1 metabolites. We conclude that the favourable cardiovascular profile of GLP-1 receptor agonists might expand their therapeutic use for treating cardiovascular disease even in non-diabetic populations. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc.

Citing Articles

Microvascular Dysfunction Following Cardioplegic Arrest and Cardiopulmonary Bypass: Impacts of Diabetes and Hypertension.

Kanuparthy M, Manthana R, Kaushik H, Xiang K, Hamze J, Marimekala D Biomedicines. 2025; 13(2).

PMID: 40002822 PMC: 11853148. DOI: 10.3390/biomedicines13020409.

A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure.

Gul U, Aung T, Martin M, Farrukh D, Shah P, Lovely Z Cureus. 2025; 16(12):e76519.

PMID: 39872560 PMC: 11771532. DOI: 10.7759/cureus.76519.

Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway.

Hegab I, El-Horany H, Abd-Ellatif R, Nasef N, Okasha A, Emam M Int J Mol Sci. 2025; 26(1.

PMID: 39795860 PMC: 11720588. DOI: 10.3390/ijms26010001.

Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration.

Yang X, Lin R, Feng C, Kang Q, Yu P, Deng Y Pharmaceutics. 2024; 16(11).

PMID: 39598478 PMC: 11597531. DOI: 10.3390/pharmaceutics16111353.

Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management.

Delrue C, Speeckaert M Int J Mol Sci. 2024; 25(17).

PMID: 39273299 PMC: 11395482. DOI: 10.3390/ijms25179351.

References

Schmidt T, Samaras P, Frejno M, Gessulat S, Barnert M, Kienegger H . ProteomicsDB. Nucleic Acids Res. 2017; 46(D1):D1271-D1281. PMC: 5753189. DOI: 10.1093/nar/gkx1029. View

Burgmaier M, Liberman A, Mollmann J, Kahles F, Reith S, Lebherz C . Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice. Atherosclerosis. 2013; 231(2):427-35. DOI: 10.1016/j.atherosclerosis.2013.08.033. View

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3. View

Vyas A, Yang K, Woo D, Tzekov A, Kovacs A, Jay P . Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One. 2011; 6(2):e17178. PMC: 3040766. DOI: 10.1371/journal.pone.0017178. View

Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B . Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010; 38(11):1944-53. DOI: 10.1124/dmd.110.034066. View

Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A . Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab. 2018; 20(9):2255-2263. DOI: 10.1111/dom.13361. View

Ban K, Kim K, Cho C, Sauve M, Diamandis E, Backx P . Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology. 2010; 151(4):1520-31. DOI: 10.1210/en.2009-1197. View

Hermansen K, Baekdal T, During M, Pietraszek A, Mortensen L, Jorgensen H . Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013; 15(11):1040-8. DOI: 10.1111/dom.12133. View

Thorens B . Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A. 1992; 89(18):8641-5. PMC: 49976. DOI: 10.1073/pnas.89.18.8641. View

10.

Baggio L, Yusta B, Mulvihill E, Cao X, Streutker C, Butany J . GLP-1 Receptor Expression Within the Human Heart. Endocrinology. 2018; 159(4):1570-1584. PMC: 5939638. DOI: 10.1210/en.2018-00004. View

11.

McCormick L, Hoole S, White P, Read P, Axell R, Clarke S . Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization. JACC Cardiovasc Interv. 2015; 8(2):292-301. DOI: 10.1016/j.jcin.2014.09.014. View

12.

Lovshin J, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker D . Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2014; 38(1):132-9. DOI: 10.2337/dc14-1958. View

13.

Gejl M, Sondergaard H, Stecher C, Bibby B, Moller N, Botker H . Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(7):E1165-9. DOI: 10.1210/jc.2011-3456. View

14.

Woo J, Kim W, Ha S, Kim J, Kim S, Kim W . Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol. 2013; 33(9):2252-60. DOI: 10.1161/ATVBAHA.113.301586. View

15.

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

16.

Hogan A, Gaoatswe G, Lynch L, Corrigan M, Woods C, OConnell J . Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2013; 57(4):781-4. DOI: 10.1007/s00125-013-3145-0. View

17.

Deacon C . Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2005; 36(11-12):761-5. DOI: 10.1055/s-2004-826160. View

18.

Bang-Berthelsen C, Holm T, Pyke C, Simonsen L, Sokilde R, Pociot F . GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation. Inflamm Bowel Dis. 2016; 22(9):2078-97. DOI: 10.1097/MIB.0000000000000847. View

19.

Yusta B, Baggio L, Koehler J, Holland D, Cao X, Pinnell L . GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. Diabetes. 2015; 64(7):2537-49. DOI: 10.2337/db14-1577. View

20.

Wang R, Lu L, Guo Y, Lin F, Chen H, Chen W . Effect of Glucagon-like Peptide-1 on High-Glucose-induced Oxidative Stress and Cell Apoptosis in Human Endothelial Cells and Its Underlying Mechanism. J Cardiovasc Pharmacol. 2015; 66(2):135-40. DOI: 10.1097/FJC.0000000000000255. View